Diabetes mellitus. Non-insulin-dependent diabetes mellitus
Conditions
Interventions
Intervention 1: Artichoke leaf extract at the dose of one 400 mg capsule every 8 hours in addition to daily two 5 mg glyburide tablets and two 500 mg metformine tablets are adminstered to a group of
Treatment - Drugs
Placebo
Artichoke leaf extract at the dose of one 400 mg capsule every 8 hours in addition to daily two 5 mg glyburide tablets and two 500 mg metformine tablets are adminstered to a group of about 30 patient
One placebo capsule every 8 hours in addition to daily two 5 mg glyburide tablets and two 500 mg metformine tablets are adminstered to a group of about 30 patients for 2 months.
Sponsors
Jahade Daneshgahi
Eligibility
Sex/Gender
All
Age
40 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Iranian male and female type 2 diabetic outpatients, patients aged 40 to 60 years, patients with fasting serum glucose levels from 150 mg/dl to 200 mg/dl, patients with blood HbA1c levels from 7% to 9% despite taking two 5 mg glyburide tablets and two 500 mg metformin tablets every day, patients using two 5 mg glyburide tablets and two 500 mg metformin tablets every day, patients with fasting serum LDL levels from 100 mg/dl to 150 mg/dl. Exclusion criteria: Patients taking other anti-hyperglycemic and anti-hyperlipidemic agents, patients receiving insulin, patients with cardiac, renal, hepatic, hematological diseases, hypothyroidism, tachycardia, vertigo and seizure, patients with a history of gallstones or gall bladder surgery, patients using estrogen, steroid, beta-blocker and thiazide, pregnant women, women planning pregnancy, breast-feeding women.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting glucose serum level. Timepoint: 2 months. Method of measurement: Medical laboratory (kit).;Glycosylated hemoglobin blood level. Timepoint: 2 months. Method of measurement: Medical laboratory (kit).;LDL serum level. Timepoint: 2 months. Method of measurement: Medical laboratory (kit). | — |
Secondary
| Measure | Time frame |
|---|---|
| SGOT serum level. Timepoint: 2 months. Method of measurement: Medical laboratory (kit).;SGPT serum level. Timepoint: 2 months. Method of measurement: Medical laboratory (kit).;Total cholesterol serum level. Timepoint: 2 months. Method of measurement: Medical laboratory (Kit).;VLDL serum level. Timepoint: 2 months. Method of measurement: Medical laboratory (kit).;HDL serum level. Timepoint: 2 months. Method of measurement: Medical laboratory (kit).;Triglyceride serum level. Timepoint: 2 months. Method of measurement: Medical laboratory (kit).;Creatinine serum level. Timepoint: 2 months. Method of measurement: Medical laboratory (kit).;2 hours postprandial glucose serum level. Timepoint: 2 months. Method of measurement: Medical laboratory (kit). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Saeed Kianbakht
Institute of Medicinal Plants affiliated with the ACECR
Outcome results
None listed